Visual Field Progression: Differences Between Normal-Tension and Exfoliative High-Tension Glaucoma KG Ahrlich, 1,3 CGV De Moraes, 2 CC Teng, 2 TS Prata,

Slides:



Advertisements
Similar presentations
Biomechanical Properties of the Cornea in Normal- Tension Glaucoma Authors: Leonidas Traipe Ines Cayuqueo Fabiola Cerfogli Claudia Goya Allister Gibbons.
Advertisements

Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Clinical Guidance and Monitoring for Change Cecilia Fenerty MD FRCOphth.
The purpose of this study is to use statistical and classification models to classify, detect and understand progression in visual fields (VFs) We intend.
A Prospective Trial Evaluating Scleral Rebound Tonometry Sara Duke, MD, Andrew Logeman, Shuchi Patel, MD Loyola University Chicago, Department of Ophthalmology,
Aqueous Humor and Plasma Levels of Vascular Endothelial Growth Factor and Nitric Oxide in Patients with Pseudoexfoliation Syndrome and Pseudoexfoliation.
Anterior Chamber Depth, Iridocorneal Angle Width, and Intraocular Pressure Changes After Phacoemulsification: Narrow vs Open Iridocorneal Angles Huang.
Phacoemulsification with Goniosynechialysis in the Management of Refractory Acute Angle-closure Glaucoma Ghasem Fakhraie*, MD, Mahmoud Jabbarvand, MD,
The Effect of the Restor Multifocal IOL on Frequency Doubling Perimetry Elizabeth Yeu, MD1, Elizabeth Woznak, BS2, Nicole Kesten, BS2, Steven VL Brown,
A significant proportion of diabetic patients develop diabetic nephropathy which can eventually progress to end-stage renal disease despite established.
Understanding Disparities Among Diagnostic Technologies in Glaucoma De Moraes C, Liebmann JM, Ritch R, Hood DC. Understanding disparities among diagnostic.
Elvin H. Yildiz, Elisabeth J. Cohen, Ajoy S. Virdi, Kristin M. Hammersmith, Peter R Laibson, and Christopher J. Rapuano Cornea Service, Wills Eye Institute,
Copyright restrictions may apply JAMA Ophthalmology Journal Club Slides: Intraocular Pressure Risk Factors Parekh A, Srivastava S, Bena J, Albini T, Nguyen.
Variations in corneal biomechanical parameters and central corneal thickness during the menstrual cycle. David Zadok, MD, Yakov Goldich, MD, Yaniv Barkana,
A Prospective Trial Comparing Scleral Pneumotonometry to Goldmann Applanation Tonometry Sara Duke, MD, Usiwoma Abugo, BS, Shuchi Patel MD Loyola University.
Somasheila I. Murthy, Prashant Garg, Pravin K. Vaddavalli
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Will my Glaucoma patient lose vision ?
Ahmad Kheirkhah MD, Rodrigo Muller MD, Deborah Pavan-Langston MD, Andrea Cruzat MD, Pedram Hamrah MD Ocular Surface Imaging Center, Massachusetts Eye and.
TARIQ ALASBALI WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?
Stratification of Normative Data
Does Greater Long-Term IOP Variability Increase Probability of Primary Open Angle Glaucoma in the Ocular Hypertension Treatment Study (OHTS)? M.O. Gordon,
Intra-eye RNFL and MT Asymmetry for the Discrimination of POAG and NTG
World Cornea Congress VI Michael K. Smolek & Panagiotis Kompotiatis Department of Ophthalmology LSU Eye Center of Excellence, New Orleans The authors.
Cataract Surgery After Trabeculectomy: The Effect on Trabeculectomy Function Husain R, Liang S, Foster PJ. Cataract surgery after trabeculectomy: the effect.
Effect of Corneal Thickness on Selective Laser Trabeculoplasty to Decrease Intraocular Pressure as Primary or Secondary Treatment of Glaucoma ASCRS 2010.
Variations in corneal biomechanical parameters and central corneal thickness during the menstrual cycle. Yakov Goldich, MD, David Zadok MD, Yaniv Barkana,
Endothelial Keratoplasty in Patients With an Anterior Chamber Intraocular Lens: A Montreal Experience Georges M. Durr, MD 1,2 Johanna Choremis, MD, FRCSC.
Comparison of Central Corneal Thickness and Peripheral Corneal Thickness using Sheimpflug system, Optical Coherence Tomography and Ultrasound Pachymetry.
How Do I Know My Glaucoma Treatment is Working? Dr Catherine Green Head: Glaucoma Unit RVEEH.
Effect of Race on Selective Laser Trabeculoplasty  1st author has no financial interest in the subject matter of this poster.  2nd and 3rd co-authors.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Visual and IOP Outcomes after PRK in Pigment Dispersion Syndrome [Poster Number: P190] Kraig S. Bower, Denise A. Sediq, Charles D. Coe, Keith Wroblewski,
Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study De Moraes CG, Demirel S, Gardiner SK, et.
The Ocular Hypertension Treatment Study Group (OHTS)
Effect of East Asian Race on Selective Laser Trabeculoplasty ASCRS 2011 Minerva Kim Johns Hopkins University Lawrence F. Jindra, MD Columbia University.
Effect of Refractive State on Selective Laser Trabeculoplasty ASCRS 2011 Kevin Lai Stony Brook University School of Medicine Elaine M. Miglino Floral Park.
Efficacy of Topical Azithromycin & Cyclosporine A(CsA) vs CsA Alone in the Treatment of Dry Eyes Associated with Blepharitis Kenneth A. Beckman, M.D.,
Comparing Factors Affecting Surgically Induced Astigmatism
Clinical Effectiveness Of Contrast Sensitivity Function In Patients With Primary Open Angle Glaucoma (POAG) And Ocular Hypertension (OHT ) MOUSUMI SAIKIA.
Poster produced by Faculty & Curriculum Support (FACS), Georgetown University School of Medicine LASIK Combined with Corneal Cross-linking in Eyes with.
The Royal Victorian Eye and Ear Hospital 24-hour eye pressure and glaucoma Dr Simon Skalicky FRANZCO, MPhil, MMed (Ophthal Sci), MBBS (Hons 1) Visiting.
Date of download: 5/29/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Confirmation of Visual Field Abnormalities in the.
Six-Year Longevity of Selective Laser Trabeculoplasty as Primary Therapy in Patients with Glaucoma ASCRS 2009 Lawrence F. Jindra, MD Columbia University.
Effect of Previous Argon Laser Trabeculoplasty on Selective Laser Trabeculoplasty ASCRS 2011 Lawrence F. Jindra, MD Columbia University Winthrop University.
Ce Zheng 1, 2, 3, John Mark S de Leon 1, Carol Y Cheung 1, Arun K Narayanaswamy 1, Sim-Heng Ong 4, Clement W Tan 2, Paul T Chew 2, Shamira A Perera 1,
D.r Nishant Nawani, MS Dr. Surinder Singh Pandav, MD Dr. Amit Gupta, MD Dr. Sushmita Kaushik, MD Advanced Eye Centre PGIMER, Chandigarh The authors have.
Nathan Lighthizer, O.D., F.A.A.O Assistant Professor, NSUOCO Chief of Specialty Care Clinics Chief of Electrodiagnostics Clinic COPE Approved: COPE # PD.
Genetic Susceptibility Variations and Visual Field Progression in Singaporean Chinese Patients with Primary Angle Closure Glaucoma 1 Duke-National University.
1. Ankara University School of Medicine, Department of Ophthalmology
and Microperimetry visual field parameters for Glaucomatous Loss
The Efficacy and Safety of the Low Intensity Ultrasound Treatment in Patients with Open Angle Glaucoma Hyoung Won Bae, Gong Je Seong, Chan Yun Kim Institute.
Halil Ates1, Suzan Guven Yilmaz1, Murat Erbezci2
cross- sectional analyses of HEIJO-KYO Cohort
시야검사의 이해 서울성모병원 안 명 덕.
Target IOP Update Mohamed Yasser Sayed Saif Beni Suef University
Characteristics of Primary Angle-Closure Glaucoma Patients with Normal Intraocular Pressure at the First Visit Won Hyuk Oh1, Bum Gi Kim1, Joo Hwa Lee2.
Safety of medication reduction for Primary Angle Closure (PAC) –
COLLABORATIVE NORMAL-TENSION GLAUCOMA STUDY GROUP
From: Visual Field Progression in Glaucoma: Estimating the Overall Significance of Deterioration with Permutation Analyses of Pointwise Linear Regression.
Review of Glaucoma Suspect
Structure-Function Relationship Between the Bruch Membrane Opening-based Minimum Rim Width and Visual Field Defects in Advanced Glaucoma Serhat Imamoglu,
Effect of Selective Laser Trabeculoplasty on
Clinical effect of citicoline combined with choline alfoscerate for treatment of glaucomatous optic neuropathy Karliychuk M.A., Pinchuk S.V. Department.
IOP = intraocular pressure; SD = standard deviation.
Risk stratification and calculators
David B Henson Medical School University of Manchester
Associate Professor of Ophthalmology
The Effect of Corneal Thickness on Ocular Drug Penetration
Presentation transcript:

Visual Field Progression: Differences Between Normal-Tension and Exfoliative High-Tension Glaucoma KG Ahrlich, 1,3 CGV De Moraes, 2 CC Teng, 2 TS Prata, 2 R Ritch, 2 JM Liebmann 1,2 1 New York University School of Medicine, New York, NY 2 Einhorn Clinical Research Center, New York Eye & Ear Infirmary, New York, NY 3 Manhattan Eye, Ear, and Throat Hospital, New York, NY Supported by the ASCRS Foundation and the Ephraim and Catherine Gildor Research Fund of the New York Glaucoma Research Institute. The authors have no financial interest in the subject matter of this poster. 1

Introduction The relative importance of IOP-dependent and IOP-independent risk factors varies among individuals and forms of glaucoma. Exfoliative glaucoma (XFG) is characteristically associated with elevated IOP (exfoliative high tension glaucoma, XHTG), and IOP- dependent factors are thought to play a central role in disease onset and progression. Glaucomatous eyes with an IOP in the statistically normal range (normal-tension glaucoma, NTG) are less dependent on IOP for disease onset and progression. It remains unclear whether the same pattern and rates of glaucomatous visual field deterioration are present in both NTG and XHTG

Purpose To compare the pattern, location, and rate of visual field (VF) loss in NTG and XHTG. 3

Methods The Glaucoma Progression Study (GAPS) consists of 43,660 consecutive subjects (132,512 VF tests) evaluated in a glaucoma referral practice from January 1999 to December Subjects with glaucomatous optic neuropathy, repeatable VF loss, ≥5 SITA-Standard VF examinations, and NTG or HTG, were enrolled. If both eyes were eligible, one was selected randomly. NTG was defined as glaucomatous VF loss and all known IOP measurements ≤21 mmHg. HTG was limited to exfoliative glaucoma (XFG), defined as glaucomatous VF loss, untreated IOP >21 mmHg, and the presence of exfoliation material on the pupillary margin and/or on the anterior lens capsule. 4

Methods VISUAL FIELD ANALYSIS Automated pointwise linear regression (PLR) analysis was performed using Progressor™ (Version 3.3, Medisoft, Inc., London, UK), providing slopes (decibels [dB]/year) of progression globally and locally for each point based on threshold maps, as well as significance (p-values). The number and location of the significantly progressing points was compared with the division of VF sectors described by Garway-Heath et al. 9 This information was used to establish the most common location of progressing points in each group. 5

Methods CLINICAL DATA Baseline central VF loss was defined by the presence of at least one point with p<0.01 within the four central-most points of the pattern deviation graph in the two consecutive baseline tests. Progression was defined as the presence of a test point with a slope of sensitivity over time >1 dB loss/year, with p 2 dB loss/year (also with p<0.01) was used. Paracentral progression was defined as progression of any of the points adjacent to the four central-most points of the VF (i.e., within the 12 central-most points). 6

Results NTG (n=139)XHTG (n=154)P-value Age (years)62.7 ± ± 9.4<0.01 Gender (women)92 (66.1%)88 (57.1%)0.14 Ethnicity (European ancestry)106 (76.2%)144 (93.5%)<0.01 Migraine/Raynaud’s/Hypotension53 (38%)6 (4%)<0.01 Cardiovascular diseases*59 (42%)86 (56%)0.02 Mean number of VF8.2 ± ± Mean follow-up time (years)5.2 ± ± Baseline mean deviation (dB)-6.5 ± ± Central defect at baseline VF82 (58.9%)49 (31.8%)<0.01 CCT (µm)533.9 ± ± Mean follow-up IOP (mm Hg)13.3 ± ± 3.2<0.01 Table 1. Baseline characteristics of the studied population. VF=visual field, NTG=normal-tension glaucoma, XHTG=exfoliative high-tension glaucoma, CCT=central corneal thickness, IOP=intraocular pressure. *Includes: hypertension, coronary ischemia, stroke. 7

Results NTG (n=139)XHTG (n=154)P-value Endpoint of progression64 (46%)75 (48.7%)0.73 Mean follow-up time of progressing eyes (days) 2102 ± ± Progression at or adjacent to central VF48/64 (75%)43/75 (57.3%)0.04 Global rate of change 1 (dB loss/year)-0.46 ± ± Localized rate of change 1 (progressing points) (dB loss/year) -2.0 ± ± Mean number of progressing points in the VF 3.7 ± ± Table 2. Intercurrent characteristics of the studied population. VF=visual field, NTG=normal-tension glaucoma, XHTG=exfoliative high-tension glaucoma, CCT=central corneal thickness, IOP=intraocular pressure. 1 Values are adjusted for differences in age, CCT, and mean IOP between groups. 8

Results Figure. Mapping of the location of significant visual progression in glaucomatous eyes that reached a progression endpoint (modified from Garway-Heath et al. 9 Significant progression was defined by any test point with a slope >1.0 dB loss/year with p 2.0 db loss/year for edge points). A, NTG; B, XHTG. 9

Discussion  We optimized the evaluation of the velocity and pattern of VF progression associated with IOP by comparing a group of patients with non-IOP-dependent factors (NTG) and one in which IOP is believed to play a predominant role (XHTG).  XHTG and NTG eyes progress at a similar global rate after adjustment for differences in CCT, IOP, and age. However, NTG eyes progress more often in the central field, independent of other factors.  The most important factor associated with paracentral progression among eyes that reached a progression endpoint was the diagnosis of NTG.  The results of our analysis of VF progression correlate well with previous studies of NTG and XHTG, despite our use of trend analysis by PLR. 10,11  Our map (figure) shows that in eyes with statistically elevated IOP, superior and inferior arcuate areas progress faster, whereas the central field may be more influenced by IOP-independent factors. This requires further clarification. 10

Conclusion NTG eyes tended to show a faster progression rate in the central field, but rates of global VF loss are similar between treated NTG and XHTG patients. Greater surveillance of the central field in NTG may be warranted, with more widespread use of alternative methods to follow NTG patients, including: visual field strategies assessing the central ten degrees multifocal visual evoked potential techniques microperimetry 11

References 1.Hitchings RA, Anderton SA. A comparative study of visual field defects seen in patients with low-tension glaucoma and chronic simple glaucoma. Br J Ophthalmol. 1983;67: Caprioli J, Spaeth GL. Comparison of visual field defects in the low-tension glaucomas with those in the high-tension glaucomas. Am J Ophthalmol. 1984;97: Chauhan BC, Drance SM, Douglas GR, Johnson CA. Visual field damage in normal-tension and high-tension glaucoma. Am J Ophthalmol. 1989;108: Araie M, Yamagami J, Suziki Y. Visual field defects in normal-tension and high-tension glaucoma. Ophthalmology. 1993;100: Araie M. Pattern of visual field defects in normal-tension and high-tension glaucoma. Curr Opin Ophthalmol. 1995;6: Thonginnetra O, Greenstein VC, Chu D, Liebmann JM, Ritch R, Hood DC. Normal versus high tension glaucoma: a comparison of functional and structural deficits. J Glaucoma [Epub ahead of print]. 7.Motolko M, Drance SM, Douglas GR. Visual field defects in low-tension glaucoma. Comparison of defects in low-tension glaucoma and chronic open angle glaucoma. Arch Ophthalmol. 1982;100: King D, Drance SM, Douglas G, Schulzer M, Wijsman K. Comparison of visual field defects in normal-tension glaucoma and high-tension glaucoma. Am J Ophthalmol. 1986;101: Garway-Heath DF, Poinoosawmy D, Fitzke FW, Hitchings RA. Mapping the visual field to the optic disc in normal tension glaucoma eyes. Ophthalmology. 2000;107: Drance S, Anderson DR, Schulzer M. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001;131: Puska P. Unilateral exfoliation syndrome: conversion to bilateral exfoliation and to glaucoma: a prospective 10-year follow-up study. J Glaucoma. 2002;11: